Form 4: Corbus Pharmaceuticals Director Rachelle Jacques Receives Significant Equity Grant

Corbus Pharmaceuticals Holdings, Inc. Director Rachelle Jacques was granted 4,800 restricted stock units and 16,000 stock options on May 30, 2025, as part of her compensation.

Summary

• On May 30, 2025, Rachelle Suzanne Jacques, a Director of Corbus Pharmaceuticals Holdings, Inc. (CRBP), was granted 4,800 restricted stock units (RSUs).
• These RSUs will be settled in shares of common stock, par value $0.0001 per share, and will vest 100% on May 30, 2026, which is the one-year anniversary from the grant date.
• Following this transaction, Ms. Jacques beneficially owns 7,583 shares of common stock, which includes the 4,800 unvested RSUs.
• Additionally, on May 30, 2025, Ms. Jacques was granted 16,000 stock options with an exercise price of $7.42 per share.
• These stock options were awarded under the issuer's 2024 Equity Compensation Plan and will also vest 100% on May 30, 2026.
• The stock options have an expiration date of May 30, 2035.
• The Form 4 filing was signed on June 2, 2025.

Sentiment

Score: 7

Explanation: The grant of equity awards to a director is a positive step for aligning management and director interests with shareholder value, reflecting standard compensation practices and signaling commitment.

Positives

• The grant of restricted stock units and stock options to a director aligns their interests with those of shareholders, incentivizing long-term value creation.
• The equity awards are part of a formal 2024 Equity Compensation Plan, indicating structured corporate governance around executive and director compensation.

Future Outlook

The granted restricted stock units and stock options are scheduled to vest 100% on May 30, 2026, contingent on continued service.

Industry Context

The granting of equity awards such as restricted stock units and stock options to directors is a common and standard practice across publicly traded companies, particularly in the biotechnology and pharmaceutical sectors, to attract, retain, and incentivize key personnel and align their long-term interests with shareholder value.

Comparison to Industry Standards

• The equity grant to a director is a standard compensation mechanism widely adopted by public companies, including those in the pharmaceutical industry, to align the interests of board members with long-term shareholder value.
• While specific comparable companies or projects are not detailed in this filing, the structure of granting RSUs and stock options with a one-year vesting period is a common industry practice for director compensation, reflecting a balance between immediate incentive and long-term commitment.

Corporate Governance

Related Party Transactions

• The grant of equity awards to Rachelle Jacques, a Director of Corbus Pharmaceuticals, constitutes a related party transaction, which is a standard form of compensation for board members.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with shareholder value, potentially leading to more focused decision-making aimed at increasing stock price.
• Employees: While not directly impacting general employees, such compensation practices for leadership can set a precedent for performance-based incentives across the organization.

Next Steps

• The vesting of the 4,800 restricted stock units and 16,000 stock options is scheduled for May 30, 2026.

Key Dates

Recommendation

Keywords

Corbus Pharmaceuticals, CRBP, SEC Form 4, Equity Grant, Restricted Stock Units, Stock Options, Director Compensation, Insider Transaction, Rachelle Jacques